Pharma shifts to strategic CDMO partnerships as complex drug programs grow

Pharmaceutical companies are reworking how they choose development and manufacturing partners as pipelines move deeper into peptides, oligonucleotides and other complex modalities. WuXi AppTec says the shift is pushing CDMOs to solve technical problems, keep quality consistent across regions and move faster without sacrificing compliance.

Why it matters: - Drug programs built around complex modalities need more than execution support. - Companies now want partners that can help solve chemistry, purification and scale-up problems earlier in development. - Global consistency matters more as programs move across regions and manufacturing stages. - Speed still matters, but developers cannot afford to trade away quality or regulatory readiness.

What happened: - WuXi AppTec framed the CDMO market as moving from a contractor model to a strategic partnership model. - The company said pipelines are expanding into peptides, oligonucleotides, targeted protein degraders and other complex modalities. - WuXi AppTec highlighted investments in technologies for harder-to-make molecules, including flow chemistry and biocatalysis. - The company also pointed to integrated peptide capabilities, including SPPS-LPPS hybrid synthesis, tangential flow filtration, continuous flow chromatography and spray drying.

The details: - Flow chemistry supports continuous manufacturing, with better reaction control, safety and scalability for complex or hazardous reactions. - Biocatalysis uses novel enzymes and ultra-high-throughput screening to shorten and simplify synthetic routes for challenging small molecules, peptides and oligonucleotides. - WuXi AppTec said its process design combines tailored solid-support strategies, custom synthesis routes and advanced analytical methods built around each molecule’s behavior. - In one case, a client developing a divalent-siRNA-GalNAc conjugate needed a complete CMC package for an IND filing within eight months. - The program had faced low yield and purity in single-strand synthesis and purification, plus an unstable impurity profile in the duplex. - WuXi AppTec said its team identified new solid-support and synthesis strategies that increased crude sense-strand purity by more than 85% and final yield by over 90%. - The company also said it built a more robust analytical method to separate key impurities from the main peak. - Multiple in-house groups worked in parallel from API through drug product development. - The materials were delivered on schedule, and the client met its IND milestone. - WuXi AppTec said its global quality approach, called the “One Global Quality System,” aligns quality standards, procedures and training across sites. - At the company’s Couvet, Switzerland site, teams transferred and scaled up Phase 3 manufacturing from a client’s own facility. - The transition covered equipment compatibility, analytical method validation and materials procurement. - WuXi AppTec said the work was completed in five months, allowing the client to submit its NDA on time. - The company said its oral peptide work has supported more than 70 preclinical programs and more than 10 clinical-phase programs.

Between the lines: - The message is less about outsourcing and more about embedding outside expertise into program strategy. - Complex molecules raise the odds of failure in route selection, purification and analytics, so technical depth becomes a competitive advantage. - A single quality system can reduce friction for sponsors running global development programs. - The examples are meant to show that CDMO value now includes problem-solving, speed and lifecycle support, not just manufacturing capacity.

What's next: - As more drug pipelines move into technically difficult modalities, demand should grow for CDMOs that can handle development, scale-up and regulatory support together. - Sponsors are likely to keep prioritizing partners that can reduce risk early and keep programs moving across clinical and commercial stages. - WuXi AppTec is positioning its platform around that need with integrated chemistry, analytics and quality systems.

The bottom line: - For complex drug candidates, the CDMO relationship is becoming a strategic extension of the development team.